| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3cceda3e3d968188bbafaaa700e3a99 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2007-12-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9c9f288fc96f4a68011c25888140ca5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_539094ed47bf54f08f6c365e04caccd0 |
| publicationDate |
2010-02-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010034816-A1 |
| titleOfInvention |
Treatment of Diabetes by at Least One Epidermal Growth Factor Receptor Specific Antibody or a Derivative Thereof |
| abstract |
The present invention relates to the use of at least one epidermal growth factor receptor specific antibody or a derivative thereof for the manufacture of a medicament for the treatment of diabetes, in particular of the advanced insulin-dependent stage of diabetes mellitus Type 1 and 2 in humans as well as in animals. |
| priorityDate |
2006-12-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |